Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
SAN DIEGO–(BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company…
Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player
Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market
Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on…
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc., (approved for listing on NYSE American under “CLDI”), a clinical-stage…
Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
FOR IMMEDIATE RELEASE July 18, 2023 LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– City of…